Hyponatremia Intervention Trial (HIT): Study Protocol of a Randomized, Controlled, Parallel-Group Trial With Blinded Outcome Assessment

Background: Hyponatremia is the most common electrolyte disorder with a prevalence of up to 30% in hospitalized patients. In contrast to acute hyponatremia where the need for immediate treatment is well-recognized, chronic hyponatremia is often considered not clinically relevant. This is illustrated...

Full description

Bibliographic Details
Main Authors: Julie Refardt, Anissa Pelouto, Laura Potasso, Ewout J. Hoorn, Mirjam Christ-Crain
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Medicine
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2021.729545/full
id doaj-79d540c0b843446b84144ff98a669dc7
record_format Article
spelling doaj-79d540c0b843446b84144ff98a669dc72021-09-06T04:56:11ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2021-09-01810.3389/fmed.2021.729545729545Hyponatremia Intervention Trial (HIT): Study Protocol of a Randomized, Controlled, Parallel-Group Trial With Blinded Outcome AssessmentJulie Refardt0Julie Refardt1Julie Refardt2Anissa Pelouto3Laura Potasso4Laura Potasso5Laura Potasso6Ewout J. Hoorn7Mirjam Christ-Crain8Mirjam Christ-Crain9Mirjam Christ-Crain10Departments of Endocrinology, Diabetology and Metabolism University Hospital Basel, Basel, SwitzerlandDepartment of Clinical Research, University of Basel, Basel, SwitzerlandClinical Trial Unit, Department of Clinical Research, University of Basel and University Hospital Basel, Basel, SwitzerlandDepartment of Internal Medicine, Division of Nephrology and Transplantation, Erasmus MC, University Medical Center Rotterdam, Rotterdam, NetherlandsDepartments of Endocrinology, Diabetology and Metabolism University Hospital Basel, Basel, SwitzerlandDepartment of Clinical Research, University of Basel, Basel, SwitzerlandClinical Trial Unit, Department of Clinical Research, University of Basel and University Hospital Basel, Basel, SwitzerlandDepartment of Internal Medicine, Division of Nephrology and Transplantation, Erasmus MC, University Medical Center Rotterdam, Rotterdam, NetherlandsDepartments of Endocrinology, Diabetology and Metabolism University Hospital Basel, Basel, SwitzerlandDepartment of Clinical Research, University of Basel, Basel, SwitzerlandClinical Trial Unit, Department of Clinical Research, University of Basel and University Hospital Basel, Basel, SwitzerlandBackground: Hyponatremia is the most common electrolyte disorder with a prevalence of up to 30% in hospitalized patients. In contrast to acute hyponatremia where the need for immediate treatment is well-recognized, chronic hyponatremia is often considered not clinically relevant. This is illustrated by reports showing that appropriate laboratory tests are ordered in <50% of patients and that up to 75% are still hyponatremic at discharge. At the same time, emerging evidence suggests an association between hyponatremia and adverse events including increased risk of mortality and rehospitalization.Methods: This is a randomized (1:1 ratio) controlled, superiority, parallel-group international multi-center trial with blinded outcome assessment. In total 2,278 participants will be enrolled. Participants will be randomly assigned to undergo either targeted correction of plasma sodium levels or standard of care during hospitalization. The primary outcome is the combined risk of death or re-hospitalization within 30 days.Discussion: All data on hyponatremia and mortality are derived from observational studies and often lack methodologic robustness. Consequently, the direct impact of hyponatremia on mortality and rehospitalization risk is still debated, resulting in a clinical equipoise whether in-hospital chronic hyponatremia should be treated or not. Therefore, a randomized controlled trial is required to study whether targeted plasma sodium correction reduces the risk of mortality and rehospitalization associated with hyponatremia.Clinical Trial Registration:www.ClinicalTrials.gov, identifier: NCT03557957.https://www.frontiersin.org/articles/10.3389/fmed.2021.729545/fullhyponatremiaSIAD(H)mortalityoutcometrialdiuretics [MeSH]
collection DOAJ
language English
format Article
sources DOAJ
author Julie Refardt
Julie Refardt
Julie Refardt
Anissa Pelouto
Laura Potasso
Laura Potasso
Laura Potasso
Ewout J. Hoorn
Mirjam Christ-Crain
Mirjam Christ-Crain
Mirjam Christ-Crain
spellingShingle Julie Refardt
Julie Refardt
Julie Refardt
Anissa Pelouto
Laura Potasso
Laura Potasso
Laura Potasso
Ewout J. Hoorn
Mirjam Christ-Crain
Mirjam Christ-Crain
Mirjam Christ-Crain
Hyponatremia Intervention Trial (HIT): Study Protocol of a Randomized, Controlled, Parallel-Group Trial With Blinded Outcome Assessment
Frontiers in Medicine
hyponatremia
SIAD(H)
mortality
outcome
trial
diuretics [MeSH]
author_facet Julie Refardt
Julie Refardt
Julie Refardt
Anissa Pelouto
Laura Potasso
Laura Potasso
Laura Potasso
Ewout J. Hoorn
Mirjam Christ-Crain
Mirjam Christ-Crain
Mirjam Christ-Crain
author_sort Julie Refardt
title Hyponatremia Intervention Trial (HIT): Study Protocol of a Randomized, Controlled, Parallel-Group Trial With Blinded Outcome Assessment
title_short Hyponatremia Intervention Trial (HIT): Study Protocol of a Randomized, Controlled, Parallel-Group Trial With Blinded Outcome Assessment
title_full Hyponatremia Intervention Trial (HIT): Study Protocol of a Randomized, Controlled, Parallel-Group Trial With Blinded Outcome Assessment
title_fullStr Hyponatremia Intervention Trial (HIT): Study Protocol of a Randomized, Controlled, Parallel-Group Trial With Blinded Outcome Assessment
title_full_unstemmed Hyponatremia Intervention Trial (HIT): Study Protocol of a Randomized, Controlled, Parallel-Group Trial With Blinded Outcome Assessment
title_sort hyponatremia intervention trial (hit): study protocol of a randomized, controlled, parallel-group trial with blinded outcome assessment
publisher Frontiers Media S.A.
series Frontiers in Medicine
issn 2296-858X
publishDate 2021-09-01
description Background: Hyponatremia is the most common electrolyte disorder with a prevalence of up to 30% in hospitalized patients. In contrast to acute hyponatremia where the need for immediate treatment is well-recognized, chronic hyponatremia is often considered not clinically relevant. This is illustrated by reports showing that appropriate laboratory tests are ordered in <50% of patients and that up to 75% are still hyponatremic at discharge. At the same time, emerging evidence suggests an association between hyponatremia and adverse events including increased risk of mortality and rehospitalization.Methods: This is a randomized (1:1 ratio) controlled, superiority, parallel-group international multi-center trial with blinded outcome assessment. In total 2,278 participants will be enrolled. Participants will be randomly assigned to undergo either targeted correction of plasma sodium levels or standard of care during hospitalization. The primary outcome is the combined risk of death or re-hospitalization within 30 days.Discussion: All data on hyponatremia and mortality are derived from observational studies and often lack methodologic robustness. Consequently, the direct impact of hyponatremia on mortality and rehospitalization risk is still debated, resulting in a clinical equipoise whether in-hospital chronic hyponatremia should be treated or not. Therefore, a randomized controlled trial is required to study whether targeted plasma sodium correction reduces the risk of mortality and rehospitalization associated with hyponatremia.Clinical Trial Registration:www.ClinicalTrials.gov, identifier: NCT03557957.
topic hyponatremia
SIAD(H)
mortality
outcome
trial
diuretics [MeSH]
url https://www.frontiersin.org/articles/10.3389/fmed.2021.729545/full
work_keys_str_mv AT julierefardt hyponatremiainterventiontrialhitstudyprotocolofarandomizedcontrolledparallelgrouptrialwithblindedoutcomeassessment
AT julierefardt hyponatremiainterventiontrialhitstudyprotocolofarandomizedcontrolledparallelgrouptrialwithblindedoutcomeassessment
AT julierefardt hyponatremiainterventiontrialhitstudyprotocolofarandomizedcontrolledparallelgrouptrialwithblindedoutcomeassessment
AT anissapelouto hyponatremiainterventiontrialhitstudyprotocolofarandomizedcontrolledparallelgrouptrialwithblindedoutcomeassessment
AT laurapotasso hyponatremiainterventiontrialhitstudyprotocolofarandomizedcontrolledparallelgrouptrialwithblindedoutcomeassessment
AT laurapotasso hyponatremiainterventiontrialhitstudyprotocolofarandomizedcontrolledparallelgrouptrialwithblindedoutcomeassessment
AT laurapotasso hyponatremiainterventiontrialhitstudyprotocolofarandomizedcontrolledparallelgrouptrialwithblindedoutcomeassessment
AT ewoutjhoorn hyponatremiainterventiontrialhitstudyprotocolofarandomizedcontrolledparallelgrouptrialwithblindedoutcomeassessment
AT mirjamchristcrain hyponatremiainterventiontrialhitstudyprotocolofarandomizedcontrolledparallelgrouptrialwithblindedoutcomeassessment
AT mirjamchristcrain hyponatremiainterventiontrialhitstudyprotocolofarandomizedcontrolledparallelgrouptrialwithblindedoutcomeassessment
AT mirjamchristcrain hyponatremiainterventiontrialhitstudyprotocolofarandomizedcontrolledparallelgrouptrialwithblindedoutcomeassessment
_version_ 1717780063098765312